Cervical Cancer Clinical Trial
Official title:
Determining the Sensitivity of Sentinel Lymph Nodes Identified With Robotic Fluorescence Imaging for Detecting Metastatic Endometrial and Cervical Cancer
Description:
This is a multi-institutional study investigating the sensitivity and negative predictive
value of sentinel lymph nodes mapped with robotic assisted near infrared imaging after
cervical injection of indocyanine green (ICG) dye for women with stage I endometrial or
cervical cancer at the time of their robotic surgical staging.
Patients will receive cervical injection of 1mg ICG after induction of anesthesia followed by
sentinel lymph node mapping using robotic assisted fluorescence imaging. The sentinel lymph
nodes identified will be removed and sent for ultraprocessing by pathology. The non-sentinel
pelvic and para-aortic (if indicated) non-sentinel nodes will be removed and sent for routine
pathologic processing according to standard of care for these surgical procedures. The
pathologic results of the sentinel and non-sentinel nodes will be evaluated for sensitivity
and negative predictive value in their ability to detect metastatic disease.
Brief Summary:
Patients with early stage endometrial and cervical cancer who are undergoing robotic surgery
to remove the uterus, cervix and lymph nodes will have dye injected into the cervix after
they are asleep from anesthesia prior to performing the surgery. During the surgery, the
surgeon will activate the robotic camera that is being used to visualize the internal organs
changing it to a special mode of imaging called near infrared imaging. The near infrared
imaging will allow the surgeon to see where the dye that was injected into the cervix has
spread. The dye travels through vessels called lymphatic channels to nodules called "sentinel
lymph nodes". These are the tissues the surgeon is most interested in removing in order to
see if there has been spread of their cancer to those nodules. The dye that travels to the
lymph nodes makes them more easily visible to the surgeon. Without the dye, these nodes are
indistinguishable from the surrounding fatty tissue.
The nodes that have dye in them will be removed from the patient and sent to the pathologist,
where they will be very closely examined, called ultrasectioning, for cancer spread. The
surgeon will remove the remaining lymphatic tissue (all of the fatty and lymphatic tissue
that surrounded the sentinel lymph node that did not stain with the dye), as these are the
"non-sentinel lymph nodes", and are the tissue that is traditionally removed with endometrial
and cervical cancer surgery as part of standard of care. These non-sentinel lymph nodes will
also be examined for evidence of cancer spread. The researchers will compare the pathology
results from the sentinel nodes and non-sentinel nodes. The researchers hypothesize that the
sentinel nodes contain cancer cells at least 90% of the time when there is cancer found in
the non-sentinel nodes.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06223308 -
A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT03367871 -
Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04537156 -
Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
|
Phase 3 | |
Recruiting |
NCT03668639 -
Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Withdrawn |
NCT04806945 -
A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer
|
Phase 3 | |
Active, not recruiting |
NCT04185389 -
Long-Term Follow-Up of HPV FOCAL Participants
|
||
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT05120167 -
Strategies for Endocervical Canal Investigation in Women With Abnormal Screening Cytology and Negative Colposcopy
|
N/A | |
Recruiting |
NCT05483491 -
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
|
Phase 1 | |
Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
Completed |
NCT05862844 -
Promise Women Project
|
N/A | |
Recruiting |
NCT04934982 -
Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IA1 With LVSI, IA2)
|
N/A | |
Recruiting |
NCT03876860 -
An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis
|
N/A | |
Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
Completed |
NCT00543543 -
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
|
Phase 3 | |
Terminated |
NCT04864782 -
QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT04226313 -
Self-sampling for Non-attenders to Cervical Cancer Screening
|
N/A |